Label: OVACE PLUS - sulfacetamide sodium shampoo
- NDC Code(s): 0178-0485-05, 0178-0485-08
- Packager: Mission Pharmacal Company
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: unapproved drug other
If you are a consumer or patient please visit this version.
- Rx Only
FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.
Each gram of OVACE ® Plus Shampoo (sodium sulfacetamide 10% w/w) contains 100 mg of sodium sulfacetamide in a vehicle consisting of cetearyl alcohol (and) PEG-3 distearoylamidoethylmonium methosulfate (and) polysorbate 60, citric acid anhydrous, cocamide MEA, cocamidopropyl betaine, ethylene glycol distearate, Flamenco Super Blue, fragrance, magnesium aluminum silicate, methylparaben, PEG-150 distearate, propylparaben, purified water, sodium chloride and sodium laureth sulfate.
Sodium sulfacetamide is C 8H 9N 2NaO 3S·H 2O with molecular weight of 254.24. Chemically, it is N-[(4-aminophenyl)sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:
Sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether.
- CLINICAL PHARMACOLOGY:
Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive Gram-positive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. There is no clinical data available on the degree and rate of systemic absorption of OVACE ® Plus Shampoo when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported.
The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium sulfacetamide are: Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardia and Actinomyces. Close
- INDICATIONS AND USAGE:
OVACE ® Plus Shampoo is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). Shake well before using.
OVACE ® Plus Shampoo is contraindicated in persons with known or suspected hypersensitivity to sulfonamides or to any of the ingredients of the product. Close
Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN. Close
FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.
General: Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. Hypersensitivity reactions may recur when a sulfonamide is readministered, irrespective of the route of administration, and cross hypersensitivity between different sulfonamides may occur. If OVACE ® Plus Shampoo produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. Under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur and appropriate observations and laboratory determinations should be performed.
Information for Patients: Patients should discontinue OVACE ® Plus Shampoo if the condition becomes worse, or if a rash develops in the area being treated or elsewhere. OVACE ® Plus Shampoo also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop.
Drug Interactions: OVACE ® Plus Shampoo is incompatible with silver preparations.
Pharmacology: OVACE ® Plus Shampoo has a bacteriostatic effect against Gram-positive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections.
Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on OVACE ® Plus Shampoo to date. Studies on reproduction and fertility also have not been performed. Chromosomal nondisjunction has been reported in the yeast, Saccharomyces cerevisiae, following application of sodium sulfacetamide. The significance of this finding to the topical use of sodium sulfacetamide in the human is unknown.
Pregnancy: Category C. Animal reproduction studies have not been conducted with OVACE ® Plus Shampoo. It is also not known whether OVACE ® Plus Shampoo can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. OVACE ® Plus Shampoo should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OVACE ® Plus Shampoo is administered to a nursing woman.
Pediatric Use: Safety and effectiveness in children under the age of 12 years has not been established.
- ADVERSE REACTIONS:
Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS). You should call your doctor for medical advice about side effects. To report a serious adverse event, call 1-800-298-1087. Close
The oral LD 50 of sulfacetamide in mice is 16.5 g/kg. In the event of overdosage, emergency treatment should be started immediately.
Manifestations: Overdosage may cause nausea and vomiting. Large oral overdosage may cause hematuria, crystalluria and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. For treatment, contact your local Poison Control Center or your doctor. Close
- DOSAGE AND ADMINISTRATION:
Apply to wet hair and massage vigorously into scalp. Rinse thoroughly. For best results, use at least twice a week or as directed by a doctor. Avoid contact with eyes or mucous membranes. Do not use on an infant less than 2 months of age. Close
- HOW SUPPLIED:
OVACE ® Plus Shampoo is available in an 8 fl. oz. (237 mL) bottle, NDC 0178-0485-08 and 5 g sample packets, NDC 0178-0485-05.
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.
Note: Protect from freezing and excessive heat. The product may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product. Keep container or packet tightly closed.
Occasionally, a slight yellowish discoloration may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration, however, presents no problem as it is readily removed by ordinary laundering without bleaches.
Mission Pharmacal Company
San Antonio, TX 78230-1355
- INGREDIENTS AND APPEARANCE
sulfacetamide sodium shampoo
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0178-0485 Route of Administration TOPICAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SULFACETAMIDE SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE - UNII:4965G3J0F5) SULFACETAMIDE SODIUM 100 mg in 1 mL Inactive Ingredients Ingredient Name Strength CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S) PEG-3 DISTEAROYLAMIDOETHYLMONIUM METHOSULFATE (UNII: 395MHJ5PUR) POLYSORBATE 60 (UNII: CAL22UVI4M) ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) COCO MONOETHANOLAMIDE (UNII: C80684146D) COCAMIDOPROPYL BETAINE (UNII: 5OCF3O11KX) GLYCOL DISTEARATE (UNII: 13W7MDN21W) MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC) METHYLPARABEN (UNII: A2I8C7HI9T) PEG-150 DISTEARATE (UNII: 6F36Q0I0AC) PROPYLPARABEN (UNII: Z8IX2SC1OH) WATER (UNII: 059QF0KO0R) SODIUM CHLORIDE (UNII: 451W47IQ8X) SODIUM LAURETH SULFATE (UNII: BPV390UAP0) Product Characteristics Color white Score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0178-0485-08 237 mL in 1 BOTTLE, PLASTIC 2 NDC:0178-0485-05 10 in 1 CARTON 2 5 mL in 1 PACKET Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 09/15/2011 Labeler - Mission Pharmacal Company (008117095)